Renalytix (GB:RENX)
LSE:RENX
Want to see GB:RENX full AI Analyst Report?
RENX Stock Chart & Stats
5.90 p
0.99 p(8.62%)
At close: 4:00 PM EST
5.90 p
0.99 p(8.62%)
Day’s Range― - ―
52-Week Range1.60 p - 15.50 p
Previous CloseN/A
Volume11.59K
Average Volume (3M)10.03M
Market Cap
£7.87M
Enterprise Value26.40M
Total Cash (Recent Filing)£9.63M
Total Debt (Recent Filing)£8.21M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding437,018,680
10 Day Avg. Volume3,807,103
30 Day Avg. Volume10,033,489
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Margin ImprovementRevenue growth and a large gross margin improvement indicate improving unit economics and early signs of product-market fit. If sustained, higher margins reduce incremental cash burn per test, improve scalability of the model, and make a path toward operating leverage more achievable as volumes rise.
Proprietary Diagnostics + AIKidneyIntelX’s combination of biomarker science and AI offers a durable competitive edge in risk stratification for kidney disease. That differentiated diagnostic capability supports adoption by health systems and payors focused on early intervention, offering structural demand in CKD management and population health programs.
Improving Cash Burn TrendReduced operating cash outflows versus the prior year signal improving spending discipline or revenue traction. While still negative, a sustained downward cash burn trend lengthens runway, lowers near-term financing needs, and provides management time to scale test volumes and commercial contracts to reach break-even.
Bears Say
Negative Equity / Stressed Balance SheetNegative equity constrains financial flexibility and typically implies dependence on external funding. It limits access to traditional debt financing, increases risk of dilution from equity raises, and reduces the company’s ability to absorb operational shocks or invest aggressively in commercial expansion over the medium term.
Large Net Losses And Negative MarginsExtremely large losses relative to revenues show the cost base is far above current scale. Persistent high negative margins require ongoing capital infusions, create execution pressure to cut costs or raise prices, and heighten the risk that the business cannot reach sustainable profitability without meaningful scale or structural cost changes.
Very Small Revenue BaseA small absolute revenue base limits the company’s ability to cover fixed costs and achieve operating leverage. Growth dependency on test volumes and reimbursement adoption creates execution risk: if clinical adoption or payor reimbursement lags, scaling revenue to absorb costs will be delayed, prolonging cash burn.
Renalytix News
RENX FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest share price was 1.60 p and its highest was 15.50 p in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is £7.87M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 166 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -0.016 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.016 p.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -0.016 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.818%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in GB:RENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―
Options Prices
Currently, No data available
---